MARKET

MLTX

MLTX

MoonLake Immunotherapeutics
NASDAQ
17.32
-0.43
-2.42%
Pre Market: 18.00 +0.68 +3.93% 07:59 03/30 EDT
OPEN
17.68
PREV CLOSE
17.75
HIGH
17.89
LOW
17.19
VOLUME
6.33K
TURNOVER
0
52 WEEK HIGH
62.75
52 WEEK LOW
5.95
MARKET CAP
1.24B
P/E (TTM)
-4.9117
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), AbSci (ABSI) and MaxCyte (MXCT)
TipRanks · 5h ago
H.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
TipRanks · 5h ago
Weekly Report: what happened at MLTX last week (0323-0327)?
Weekly Report · 6h ago
MoonLake's Sonelokimab Shows Strong Week 40 Results With 62% Achieving HiSCR75
NASDAQ · 7h ago
Reported Saturday, MoonLake's Phase 3 VELA Trials Show Sonelokimab Achieves 62% HiSCR75 And Up To 32% HiSCR100 At Week 40 In Moderate-To-Severe Hidradenitis Suppurativa
Benzinga · 9h ago
MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial
TipRanks · 1d ago
MoonLake sonelokimab hits 62% HiSCR75 at Week 40 in Phase 3 HS trials
Reuters · 1d ago
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Barchart · 2d ago
More
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Webull offers MoonLake Immunotherapeutics stock information, including NASDAQ: MLTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MLTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MLTX stock methods without spending real money on the virtual paper trading platform.